In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida
about
Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance PIn vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformansEvaluation of Etest method for determining posaconazole MICs for 314 clinical isolates of Candida speciesInteraction between posaconazole and amphotericin B in concomitant treatment against Candida albicans in vivoComparison of pathogenesis and host immune responses to Candida glabrata and Candida albicans in systemically infected immunocompetent mice.In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles.Investigational antifungal agents.Evaluation of disk diffusion method for determining posaconazole susceptibility of filamentous fungi: comparison with CLSI broth microdilution method.Drug strategies targeting CYP51 in neglected tropical diseasesIn vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection.Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase.Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasisKilling of Aspergillus fumigatus by alveolar macrophages is mediated by reactive oxidant intermediates.New and emerging antifungal agents: impact on respiratory infections.Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adultsPosaconazole: clinical pharmacology and potential for management of fungal infections.Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations.Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections.Developments in the treatment of candidiasis: more choices and new challenges.Antifungal prophylaxis following reduced-intensity stem cell transplantation.Posaconazole: a new broad-spectrum antifungal agent.Activity of posaconazole in treatment of experimental disseminated zygomycosis.Management of fungal infections following allogeneic stem cell transplantation.The Mechanistic Targets of Antifungal Agents: An Overview.Antifungal activities of posaconazole and granulocyte-macrophage colony-stimulating factor ex vivo and in mice with disseminated infection due to Scedosporium prolificans.Posaconazole is a potent inhibitor of sterol 14alpha-demethylation in yeasts and molds.Use of posaconazole in the treatment of invasive fungal infections.Posaconazole-Loaded Leukocytes as a Novel Treatment Strategy Targeting Invasive Pulmonary Aspergillosis.Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole.Efficacy of posaconazole in a murine model of central nervous system aspergillosis.Posaconazole: a next-generation triazole antifungal.Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.Posaconazole: An Update of Its Clinical Use.Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro.Ocular and systemic posaconazole(SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis.Mechanism of azole antifungal activity as determined by liquid chromatographic/mass spectrometric monitoring of ergosterol biosynthesis.
P2860
Q24535844-37753430-191C-4460-8F35-D89A36F2AAA3Q28353303-200E70ED-C153-46BA-B7EE-A9EFD2675F96Q28362760-FEE2501F-A3D7-4BA5-8B17-4E1B39AB74A8Q33803508-56DC83A8-65CD-4DBC-BBC5-4B55F27DACB2Q34008664-84F2CCBB-1E72-4F3B-93C4-E9E30C0AD517Q34109559-436FFE13-50F1-4651-8FA7-5BDF352AC2EFQ34141180-C17C0DDF-2E32-4644-A2A9-C4F70D5CCEFAQ34335243-21EEA2AF-F6A2-4E42-ADF0-524F69328AF2Q34509838-CC25E794-035E-42E5-83D8-EC138A91F88FQ34622554-12517284-9404-436C-9806-BAEBD8B9F508Q34680661-793BD67C-F479-4F6E-91D0-56204C11E0E0Q34721750-A1033894-A3F7-46B7-8FE1-2EE27EA15AB8Q34823914-7F310D98-99E2-446D-BD08-1FA8C20DABEEQ35007030-223FF189-C13B-46E6-92DB-24553E1E867DQ35011464-665F47C4-54B9-45CB-8891-92AAA8080099Q35627629-A86ADB36-587E-430E-B640-C09C8BF53952Q35685548-818DD1D2-61E6-45EA-809E-259C86005DBAQ36233491-51D56A27-BDB9-4B18-81E9-EC3304B5886AQ36424973-EA6C6218-E082-4B1A-8895-266DEA0794FAQ36491819-563DC8C7-D6FE-4C88-9D63-A0DAC2939230Q36589297-09AE8ED1-6DB0-4948-9E20-06DAAA6E12CBQ36623050-E76EEA31-8D64-40D0-9991-D598C6DD848EQ36658236-6D7F6FAB-D4F5-4609-9006-B154F956E7E8Q36828159-CEECE799-9EF1-4F26-8C6E-75AF72278949Q36880761-6C248ABE-BB3F-4F1A-A88A-3AB60BFADA53Q37202860-DCE55A8C-5886-47CF-8119-542CFF094A8AQ37562147-8A5C65A9-0A4E-4A93-BB3B-2E96AE3C886EQ37568516-6693B519-F8BC-4FAF-B478-597225BA85F3Q37568607-37386A3F-C115-4C88-BFC7-3D363F3DECEBQ37810083-CD504587-FDAA-4527-977C-F4690C7A64F0Q38734661-FA98AA3F-2C49-4672-A3E4-A231A738945EQ38899363-1E666C0D-3B9D-452A-A0A7-8D0D275DD449Q40164914-72BF5299-1CF5-4051-AFE1-CEB7425CA3D0Q40188974-39CBC252-0352-4F9B-840B-299FEB03DE47Q41842788-FB260BF3-44DB-4CDF-892C-DAD77172DAE0Q42144246-04D68F91-C5FF-4A7E-A246-E8CC4698C704Q42686004-B54B654A-129F-40BC-994B-5FF2C9983A77Q42956812-18BA6FFD-96FC-4B7E-A0A6-DFD188022190Q43009399-EAFB4ED3-0C62-40D5-A096-B394CBACEA30Q43938733-DAE64142-1A4D-4113-A915-675E4418980F
P2860
In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
In vitro and in vivo activitie ...... gainst Aspergillus and Candida
@ast
In vitro and in vivo activitie ...... gainst Aspergillus and Candida
@en
In vitro and in vivo activitie ...... gainst Aspergillus and Candida
@nl
type
label
In vitro and in vivo activitie ...... gainst Aspergillus and Candida
@ast
In vitro and in vivo activitie ...... gainst Aspergillus and Candida
@en
In vitro and in vivo activitie ...... gainst Aspergillus and Candida
@nl
prefLabel
In vitro and in vivo activitie ...... gainst Aspergillus and Candida
@ast
In vitro and in vivo activitie ...... gainst Aspergillus and Candida
@en
In vitro and in vivo activitie ...... gainst Aspergillus and Candida
@nl
P2093
P2860
P1476
In vitro and in vivo activitie ...... gainst Aspergillus and Candida
@en
P2093
A Cacciapuoti
B Antonacci
C Mendrick
D Loebenberg
E Corcoran
G H Miller
P2860
P304
P356
10.1128/AAC.44.8.2017-2022.2000
P407
P577
2000-08-01T00:00:00Z